Medovate
Medovate is a Cambridge-based medical device developer spun out of the NHS in 2017 that commercialises clinician-originated innovations including the SAFIRA regional anaesthesia system, Glucosave, Humidicare, LUMEVAC, and CamPROBE, sold globally through exclusive regional distributors to hospitals and clinical practices.
- Company typePrivate
- Founded2017
- HeadquartersCambridge, United Kingdom
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
Medovate firmographics
Firmographics- Name
- Medovate
- Legal name
- Medovate Limited
- Website
- https://medovate.co.uk
- Company type
- Private
- Founded year
- 2017
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Medovate is a Cambridge-based medical device developer spun out of the NHS in 2017 that commercialises clinician-originated innovations including the SAFIRA regional anaesthesia system, Glucosave, Humidicare, LUMEVAC, and CamPROBE, sold globally through exclusive regional distributors to hospitals and clinical practices.
- Ownership category
- akta.pro rank
Medovate industry classification
Industry- Product category
- Medical Devices
- NAICS
- Surgical and Medical Instrument Manufacturing (339112), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Medical Equipment and Supplies Manufacturing (3391)
- SIC
- Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845)
- akta.pro primary industry
- Anesthesia & Airway Management Equipment (Workstations, Laryngoscopy, Ventilation adjuncts) (HLAHADAJ)
- akta.pro secondary industries
- Open & Minimally Invasive Surgical Instruments (Handheld, Laparoscopic, MIS) (HLAHADAA), Endoscopic Therapeutic & Access Devices (Trocars, dilators, biopsy/ablation tools) (HLAHADAN)
Keywords
Where Medovate is headquartered
LocationHeadquarters
- HQ city
- Cambridge
- HQ country
- United Kingdom
- HQ region
- Europe
Offices2 records
Markets served
Medovate business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Supply Chain, Marketing or Sales, Operations, Infrastructure
Revenue model
- Medical Device Sales: Sale of proprietary medical devices including SAFIRA system, Glucosave, Humidicare, LUMEVAC, and CamPROBE. Revenue generated through direct sales and distributor partnerships across global markets.
- Distribution Partnerships: Revenue generated through exclusive and non-exclusive distribution agreements with regional partners across multiple territories including US, Europe, Middle East, Australia, and New Zealand.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Other | No public pricing tiers disclosed |
Go-to-market motion2 records
Distribution channels11 records
Marketing channels5 records
Medovate product offering
Product offeringCore offering
Medovate develops and commercializes a portfolio of proprietary Class II medical devices invented by NHS clinicians, focused on patient safety in anaesthesia, airway management, critical care, and surgery. Its flagship product SAFIRA® transforms regional anaesthesia into a single-operator procedure with built-in automatic injection pressure limiting. Additional products include Glucosave® (insulin safety in critical care), Humidicare® (heat and moisture exchanger with dual humidification alerts), LUMEVAC™ (endoluminal vacuum therapy for GI leaks), and CamPROBE (transperineal prostate biopsy device), with a veterinary variant of SAFIRA also commercialized.
Product overview
Medovate is a medical device development company that commercialises innovative technologies created within the NHS. The company offers a portfolio of medical devices focused on anaesthesia, airway management, critical care, and surgery. The core product portfolio includes SAFIRA® (regional anaesthesia system with pressure-limiting safety feature), CamPROBE (prostate biopsy device), Glucosave® (insulin safety device for critical care), Humidicare® (heat and moisture exchanger with dual humidification alert), and LUMEVAC™ (endoluminal vacuum therapy device for GI leaks). SAFIRA® is the company's flagship commercially launched product, while other products are at various stages of development and commercialisation. All devices are developed in collaboration with NHS clinicians to address unmet clinical needs and improve patient safety.
Differentiator
Problem solved
Functional benefit
Brands
- SAFIRA®: SAFer Injection for Regional Anaesthesia - a pioneering medical device that transforms regional anaesthesia into a single operator procedure with built-in safety mechanism to limit injection pressure.
- Glucosave®
- Humidicare®
- LUMEVAC™
- CamPROBE
Products and services
- SAFIRA® Pioneering medical device that transforms regional anaesthesia into a single-operator procedure with a built-in safety mechanism that automatically limits injection pressure to reduce the risk of nerve injury. Consists of a proprietary syringe, driver, and foot pedal or palm operator.
- CamPROBE Safe, simple, and cost-effective solution intended to facilitate transperineal prostate biopsies under simultaneous local anaesthetic delivery.
- Glucosave® Patient safety solution to help prevent inappropriate administration of insulin to patients in critical care settings.
- Humidicare® Novel heat and moisture exchanger (HME) that visually alerts clinicians to the presence of both active and passive humidification devices in mechanical breathing circuits, preventing potentially fatal airway occlusion from dual humidification errors.
- LUMEVAC™ Pioneering endoscopic surgical device for endoluminal vacuum therapy (EVT) to help improve survival of patients with life-threatening infection following gastrointestinal tract leakage after procedures such as esophagectomy, enabling treatment without general anaesthesia.
- SAFIRA® for Veterinary Applications Application of SAFIRA regional anaesthesia technology for small animal veterinary practice, enabling single-operator procedures with automatic pressure limiting for nerve safety in orthopaedic and soft tissue procedures.
Quantifiable outcome
- Automatic injection pressure limiting to below 20psi reduces nerve injury risk
- +3 more outcomes
Companies that use Medovate
Customer profileNamed customers3 records
Segments6 records
Ideal customer profiles5 records
Medovate technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
Medovate partnerships and signals
Strategic signalScale indicators6 records
Recent moves7 records
Expansion highlights6 records
Medovate competitors and assessment
Company assessmentDirect peers
- Conmed: US-listed medical device company with general surgery, endoscopic, and urology portfolios. Directly competes with LUMEVAC in endoscopic surgery and with CamPROBE in prostate biopsy.
- Penumbra: US-based medical device company with the REALTA endoluminal vacuum therapy system. Direct competitor to LUMEVAC in treating GI anastomotic leaks with EVT.
- Intersurgical: European specialist in airway management, breathing circuits, and HME products. Directly competes with Humidicare in heat and moisture exchangers and dual humidification safety.
- Pajunk: Germany-based specialist in regional anesthesia needles, catheters, and injection systems. Direct product overlap with SAFIRA in regional anesthesia nerve block procedures.
- Teleflex: Major anesthesia and interventional device company with regional anesthesia and Arrow product lines. Directly competes with SAFIRA in regional anesthesia and overlaps with airway management products comparable to Humidicare.
Broad incumbents
- Olympus Medical: Leading endoscopy and surgical device manufacturer. Competes with LUMEVAC in endoscopic GI therapeutic devices and adjacent endoscopy markets.
- B. Braun: Global medical device manufacturer with a leading regional anesthesia portfolio (Perifix) and broad anesthesia/critical care offering. Directly competes with SAFIRA in regional anesthesia and competes in adjacent anesthesia/airway segments.
- Smiths Medical (ICU Medical): Broad portfolio of anesthesia, airway management, and critical care devices. Competes with Medovate across regional anesthesia, HME/breathing circuits, and infusion safety categories.
- Medtronic: Largest medical device company globally with broad anesthesia, surgical, and urology portfolios. Overlaps with Medovate in regional anesthesia, endoscopic surgery (LUMEVAC), and prostate biopsy (CamPROBE) categories.
Emerging players
- Vygon: Global medical device company focused on anesthesia and neonatal products, and current Medovate distribution partner for SAFIRA across 60 countries. Sells its own regional anesthesia and anesthesia accessories, giving partial product overlap.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks5 records
Key highlights7 records
Customer concentration
Medovate social profiles
Digital presenceMedovate compliance and trust
Trust signalCompliance3 records
Medovate financial estimates
Financial estimateRevenue estimate
Valuation estimate
Medovate leadership team
Management profileNumber of profiles
Profiles4 records
Medovate funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Medovate M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Medovate
What does Medovate do?
Medovate develops and commercializes a portfolio of proprietary Class II medical devices invented by NHS clinicians, focused on patient safety in anaesthesia, airway management, critical care, and surgery. Its flagship product SAFIRA® transforms regional anaesthesia into a single-operator procedure with built-in automatic injection pressure limiting. Additional products include Glucosave® (insulin safety in critical care), Humidicare® (heat and moisture exchanger with dual humidification alerts), LUMEVAC™ (endoluminal vacuum therapy for GI leaks), and CamPROBE (transperineal prostate biopsy device), with a veterinary variant of SAFIRA also commercialized.
Is Medovate a public or private company?
Medovate is a private company. It is classified as venture growth investor backed and is currently operating.
When was Medovate founded?
Medovate was founded in 2017. It employs 1 to 10 people.
Where is Medovate based?
Medovate is headquartered in Cambridge, United Kingdom, in the Europe region.
How does Medovate make money?
Two revenue lines are on record. Medical Device Sales are the primary driver. The others are distribution Partnerships.
Who are Medovate's main competitors?
Direct peers on record are Conmed, Penumbra, Intersurgical, Pajunk and Teleflex. Broad incumbents are Olympus Medical, B. Braun, Smiths Medical (ICU Medical) and Medtronic. Vygon is listed as an emerging player.
Does Medovate have an API?
No public API is recorded for Medovate.
What industry is Medovate in?
Medovate's product category is Medical Devices. Its primary akta.pro industry code is HLAHADAJ, Anesthesia & Airway Management Equipment (Workstations, Laryngoscopy, Ventilation adjuncts), with a secondary code of HLAHADAA, Open & Minimally Invasive Surgical Instruments (Handheld, Laparoscopic, MIS). Its NAICS code is 339112 and its SIC code is 3841.